Dr. Holmes Answers the Question: Who is the right WATCHMANTM Patient?

Dr. David Holmes, one of the pioneers of the WATCHMAN device, chats with Dr. Craig Thompson about this breakthrough therapy and what it means for patients with non-valvular atrial fibrillation.

 “Boston Scientific is thrilled to be the first company to offer this innovative, proven, and life-enhancing therapy to patients meeting the indication for use.”

-- Ken Stein, MD, Senior Vice President and Chief Medical Officer of Rhythm Management

New Data Release

Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation

A Patient-Level Meta-Analysis

View article